Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial  

作　　者：Hong-Yu Xiang Yin-Hua Liu Hong Zhang Shuang Zhang Ling Xin Ling Xu Jing-Ming Ye Ting Li Xue-Ning Duan Qian Liu 

机构地区：[1]Breast Disease Center,Peking University First Hospital,Beijing 100034,China [2]Department of Pathology,Peking University First Hospital,Beijing 100034,China

出　　处：《Chinese Medical Journal》2019年第24期2914-2919,共6页中华医学杂志（英文版）

基　　金：This study was supported by a grant from the Beijing Medical Award Foundation(No.2018-0304).

摘　　要：Background:The results of the Trial Assigning IndividuaLized Options for Treatment(TAILORx)suggested that approximately 70%of T1-2N0M0,hormone receptor-positive,human epidermal growth factor receptor 2(HER2)-negative breast cancer patients can avoid chemotherapy and receive only adjuvant endocrine therapy.We conducted a retrospective analysis of the clinicopathologic features and prognostic factors of patients with breast cancer who met the inclusion criteria of the TAILORx trial.Methods:According to the enrollment criteria of the TAILORx trial,a retrospective analysis was performed on patients with breast cancer who were treated from January 2008 to December 2015 at Peking University First Hospital.The clinicopathologic characteristics of all patients were analyzed,and prognoses were calculated using the Kaplan-Meier method and a Cox proportionate hazards model.Results:A total of 2430 patients with early stage breast cancer who were admitted at our hospital had complete clinicopathologic data and follow-up information.Of these patients,722 met the inclusion criteria and were enrolled in the present study,accounting for 29.7%of all patients.Among them,417(57.8%)patients received only adjuvant endocrine therapy(the non-chemo group),and 305(42.2%)patients received adjuvant chemotherapy followed by adjuvant endocrine therapy(the chemo group).No statistically significant difference was observed in overall survival(OS)between the two groups(non-chemo vs.chemo:5-year OS:97.9%vs.97.9%,χ^2=1.00,P=0.995;hazard ratio[HR]=1.00,95%confidence interval[CI]:0.46–2.21).A significant difference was observed in disease-free survival(DFS)between the two groups(non-chemo vs.chemo:5-year DFS:97.9%vs.94.7%,χ^2=8.65,P=0.003;HR=3.05,95%CI:1.40–6.67).The choice of adjuvant therapy was associated with clinicopathologic factors,such as the age at diagnosis,T stage,histologic grade,the Ki67 index,the presence of intravascular tumor thrombus(P<0.001),pathologic type,and menstrual status(P=0.014).Conclusions:In the absence of internatio

关 键 词：ADJUVANT therapy Early stage BREAST cancer MULTIGENE detection Prognosis TAILORx TRIAL 

分 类 号：R73[医药卫生—肿瘤]